Could This Potential Move Boost Eli Lilly's Prospects?

Key Points Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market. There are plenty of reasons to like the stock beyond this development. 10 stocks we like better than Eli Lilly › Everything seems to be going well for Eli Lilly (NYSE: LLY). The company's shares have soared in recent years thanks to strong clinical progress within its GLP-1 franchise. The drugmaker has established itself as a leader in the fast-gr ...